A venture capital firm that seeks to digitize the life sciences ecosystem has plans for a $500 million follow-up fund, ...

A nimble Houston startup has raised a concise $28.4 million Series A to start a mid-stage trial. The company, named March ...

The UK medicines authority approved Eli Lilly’s Alzheimer’s drug Kisunla on Wednesday, making it the third major market to ...

Merck is acquiring a startup spun out of Yale called Modifi Bio, which has developed a suite of molecules against ...

Roche’s competition in the eye disease space is intensifying with Renegeron’s high-dose Eylea and looming biosimilar ...

The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints ...

Four senators want to know more about Pfizer and Eli Lilly’s partnerships with telehealth providers, and whether that may ...

Be Bio's $82 million round announced Tuesday will help the Cambridge, MA-based biotech fund work for two of its drugs in ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

Starboard Value, the activist investor pushing for changes at Pfizer, unveiled its goals for another healthcare company — ...

A panel of DC-focused lawyers predicted that the anti-China Biosecure Act is likely headed for final passage during the ...

A US drug pricing watchdog has raised the range by which it thinks Pfizer’s heart muscle disease drug tafamidis, marketed as ...